BioSpace News Archive

Toshiba Medical Systems Officially Becomes Canon Medical Systems

Canon announced that the change of the company name enters into effect today.

January 4, 2018
·
3 min read
Pharming Announces Further Conversion of its Ordinary Convertible Bonds

The newly issued shares represent 4.6% of the outstanding share capital immediately prior to the issue.

January 4, 2018
·
5 min read
Policy

Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in Europe

Alimera submitted the results from two, randomized, double-masked, multi-center phase 3 clinical trials.

January 4, 2018
·
6 min read
Business

Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer

Dr. Melnick to lead clinical team as Spero prepares to enter late-stage clinical trials.

January 4, 2018
·
4 min read
Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases

The financing was led by a syndicate of leading international life science investors including Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners.

January 4, 2018
·
3 min read
Pharm Country

Feinstein Institute Researcher Awarded $1.2M to Continue Sepsis Research

Feinstein Institute for Medical Research Professor Haichao Wang, PhD, received a $1.2M grant from the NIH NIGMS to continue his search to identify different proteins associated with sepsis, which could lead to a targeted treatment for the condition.

January 4, 2018
·
2 min read
Business

Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors

Mr. Perez has been the founder and managing partner of Vineyard Sound Advisors since 2015.

January 4, 2018
·
2 min read
Median Technologies Ranks in Deloitte Technology Fast 500 EMEA for 2017

Median grew by 428% over the period with increasing demand of the company’s medical imaging contract research services or iCRO.

January 4, 2018
·
4 min read
Drug Development

Foamix Pharma’s Acne Drug Performs in Late-Stage Study

Patients continued for up to an additional 40 weeks of open-label treatment with FMX-101.

January 4, 2018
·
5 min read
Celtaxsys Secures Private Financing to Advance Acebilustat Phase III Cystic Fibrosis (CF) Program Preparatory Activities

In conjunction with the financing, Khalil Barrage, Managing Director at Invus, will join Celtaxsys’ board of directors.

January 4, 2018
·
4 min read